ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pain Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,653Medicare Part D Prescriptions Filled, Including Refills
$1.31M Total Retail Price of All Prescriptions
782 Patients Receiving at Least One Drug in Part D
31%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
HYDROCODONE-ACETAMINOPHEN 2,250 677 S3
OXYCODONE HCL-ACETAMINOPHEN 1,319 390 S2 10
OXYCODONE HCL 965 130 S2
MORPHINE SULFATE ER 885 315 S2
METHADONE HCL 750 183 S2
OXYCONTIN 663 128 S2
GABAPENTIN 624 177
FENTANYL 591 202 S2
ENDOCET 451 142 S2
ZOLPIDEM TARTRATE 343 83
OPANA ER 292 18 S2
CARISOPRODOL 218 29 R
TIZANIDINE HCL 217 28
MELOXICAM 212 68
TOPIRAMATE 205 20
LAMOTRIGINE 201 59
BACLOFEN 182 24
CYCLOBENZAPRINE HCL 182 29 R
METHOCARBAMOL 178 34 R
LYRICA 161 11
ALPRAZOLAM 152 37
CITALOPRAM HBR 151 18
PROMETHAZINE HCL 146 25 R
HYDROMORPHONE HCL 132 30 S2
OXYCODONE-ACETAMINOPHEN 114 83 S2
CYMBALTA 113 0
MORPHINE SULFATE 104 28 S2
PREDNISONE 102 23
TEMAZEPAM 94 46
CLONAZEPAM 85 12
LIDODERM 77 11
SERTRALINE HCL 75 0
CELEBREX 75 23
DIAZEPAM 74 16
DICLOFENAC SODIUM 72 18
AMITRIPTYLINE HCL 59 0 R
TRAZODONE HCL 57 22
FLUOXETINE HCL 56 16
VENLAFAXINE HCL ER 54 24
TRAMADOL HCL 51 20
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 30, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.